Phase II Trial of PTK787/ZK222584 in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Who Failed First-Line Gemcitabine Therapy.

Inclusion Criteria:

- Age > 18

- Zubrod performance status of 0 - 2

- Histological or cytological diagnosis of pancreatic adenocarcinoma

- Measurable or evaluable disease determined as per RECIST criteria

- Life expectancy > 12 weeks

- Written informed consent

- Patients must have failed or progressed on prior gemcitabine-based therapy for
advanced or metastatic disease.

Exclusion Criteria:

- Islet cell or neuroendocrine carcinomas of the pancreas.

- History or presence of central nervous system disease.

- Patients with a history of another primary malignancy < 5 years

- Prior chemo therapy < 21 days prior to registration.

- Prior biologic or immunotherapy < 14 days prior to registration

- Prior full field radiotherapy < 28 days or limited field radiotherapy < 14 days prior
to registration.

- Major surgery < 28 days prior to registration.

- Patients who have received investigational drugs < 28 days prior to registration.

- Prior therapy with anti-VEGF agents.

- Pleural effusion or ascites that causes respiratory compromise.

- Female patients who are pregnant or breast feeding.